Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Barbara Holzer, Broadcast Manager
w. (202) 588-7716
bholzer@citizen.org

Karilyn Gower, Press Officer
w. (202) 588-7779
kgower@citizen.org

Dan Hockensmith, Communications Officer (Global Trade Watch)
w. (202) 454-5108
dhockensmith@citizen.org

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog
Facebook/publiccitizen

Follow us on Twitter

 

Jan. 10, 2013

FDA Should Reject Dangerous Diabetes Medication, Public Citizen Tells Advisory Committee

Canagliflozin, Part of a New Class of Diabetes Drugs, Presents Too Many Risks to Patients

WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) should not approve the diabetes drug canagliflozin because it could significantly harm patients and does not present significant benefit over current medications, Public Citizen said today.

In testimony today before an FDA advisory committee, director of Public Citizen’s Health Research Group Dr. Sidney Wolfe warned that the new drug presents an unsafe increase of risk for low blood pressure symptoms, adverse cardiac events, and genital and urinary infections. He urged the panel to recognize that in no way do these risks outweigh potential benefit over existing diabetes treatments.

Canagliflozin is part of a new class of diabetes drugs called sodium glucose co-transporter-2 inhibitors that work by blocking re-absorption of glucose by the kidney and increasing glucose excretion in the urine to lower blood sugar. This results in a large loss of sugary fluids. Traditional diabetes treatments typically work by improving insulin secretion or insulin sensitivity.

“The fact that the drug works by a uniquely new mechanism to lower blood sugar has not spared of a whole set of unique new risks,” said Wolfe. “The FDA has previously made too many mistakes in approving drugs, including those for diabetes, with no unique clinical benefits and unique risks. The agency shouldn’t approve this one.”

To read today’s testimony, visit: http://www.citizen.org/hrg2091.

###

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.